Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D7MJ
|
||||
| Former ID |
DIB005168
|
||||
| Drug Name |
CNSB-001
|
||||
| Synonyms |
Flupirtine + opioid (fixed dose, diabetic neuropathic pain), CNSBio; Flupirtine + opioid (fixed dose, diabetic neuropathic pain), Relevare
|
||||
| Indication | Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0] | Phase 2 | [548808] | ||
| Company |
Relevare Pharmaceuticals Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | KCNQ voltage-gated potassium channel | Target Info | Agonist | [530882] | |
| Opioid receptor | Target Info | Agonist | [544320] | ||
| References | |||||
| Ref 530882 | The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J Peripher Nerv Syst. 2010 Mar;15(1):63-72. | ||||
| Ref 544320 | Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.